The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
Abstract
Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.Methods We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial fibrillation who were randomised to receive new oral anticoagulants or warfarin, and trials in which both efficacy and safety outcomes were reported. We did a prespecified meta-analysis of all 71,683 participants included in the RE-LY, ROCKET AF, ARISTOTLE, and ENGAGE AF-TIMI 48 trials. The main outcomes were stroke and systemic embolic events, ischaemic stroke, haemorrhagic stroke, all-cause mortality, myocardial infarction, major bleeding, intracranial haemorrhage, and gastrointestinal bleeding. We calculated relative risks (RRs) and 95% CIs for each outcome. We did subgroup analyses to assess whether differences in patient and trial characteristics affected outcomes. We used a random-effects model to compare pooled outcomes and tested for heterogeneity.Findings 42,411 participants received a new oral anticoagulant and 29,272 participants received warfarin. New oral anticoagulants significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0·81, 95% CI 0·73-0·91; p<0·0001), mainly driven by a reduction in haemorrhagic stroke (0·49, 0·38-0·64; p<0·0001). New oral anticoagulants also significantly reduced all-cause mortality (0·90, 0·85-0·95; p=0·0003) and intracranial haemorrhage (0·48, 0·39-0·59; p<0·0001), but increased gastrointestinal bleeding (1·25, 1·01-1·55; p=0·04). We noted no heterogeneity for stroke or systemic embolic events in important subgroups, but there was a greater relative reduction in major bleeding with new oral anticoagulants when the centre-based time in therapeutic range was less than 66% than when it was 66% or more (0·69, 0·59-0·81 vs 0·93, 0·76-1·13; p for interaction 0·022). Low-dose new oral anticoagulant regimens showed similar overall reductions in stroke or systemic embolic events to warfarin (1·03, 0·84-1·27; p=0·74), and a more favourable bleeding profile (0·65, 0·43-1·00; p=0·05), but significantly more ischaemic strokes (1·28, 1·02-1·60; p=0·045).Interpretation This meta-analysis is the first to include data for all four new oral anticoagulants studied in the pivotal phase 3 clinical trials for stroke prevention or systemic embolic events in patients with atrial fibrillation. New oral anticoagulants had a favourable risk-benefit profile, with significant reductions in stroke, intracranial haemorrhage, and mortality, and with similar major bleeding as for warfarin, but increased gastrointestinal bleeding. The relative efficacy and safety of new oral anticoagulants was consistent across a wide range of patients. Our findings offer clinicians a more comprehensive picture of the new oral anticoagulants as a therapeutic option to reduce the risk of stroke in this patient population.Funding None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) markedly reduces stroke and mortality in AF patients.38,39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“and hence there is strong evidence that patients with a CHA 2 DS 2 -VASc risk score of 2 or more in men, and 3 or more in women benefit from OAC.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke, 38,39,42,194,201,329,351,352”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Mortality was 10% lower in patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85-0.95;P = 0.0003) and intracranial haemorrhage was halved (RR 0.48; 95% CI 0.39-0.59;P < 0.0001), while gastrointestinal bleeding events were more frequent (RR 1.25; 95% CI 1.01-1.55;P = 0.04).39”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“NOACs in these dosages significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73-0.91;P < 0.0001), mainly driven by a reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38-0.64;P < 0.0001).”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“A meta-analysis 39 based on the highdose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a NOAC and 29,272 receiving warfarin.”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
In the citing paper
“Good data are available to support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of the Aged Study), 362 the NOAC trials, 39 and from analyses in elderly Americans (Medicare).396”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [39]
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Kirchhof, P. F., Lip, G. Y. H., Schotten, U., Savelieva, I., Ernst, S., Gelder, I. C. V., Al‐Attar, N., Hindricks, G., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq278 · Cited by 5,924
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · CHEST Journal · doi:10.1378/chest.10-0134 · Cited by 4,517
Cited by
Sorted by citations
Items 501–600 of 1,004
News at XI: moving beyond factor Xa inhibitors
Fredenburgh, J. C., & Weitz, J. I. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.04.021 · Cited by 63
Urgent Need to Measure Effects of Direct Oral Anticoagulants
Weitz, J. I., & Eikelboom, J. W. (2016) · Circulation · doi:10.1161/circulationaha.116.022307 · Cited by 62
Flack, K. F., Desai, J., Kolb, J. M., Chatterjee, P., Wallentin, L. C., Ezekowitz, M. D., Yusuf, S., Connolly, S. J., Reilly, P. A., Brueckmann, M., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.10.011 · Cited by 62
Gamble, J. H. P., Herring, N., Ginks, M., Rajappan, K., Bashir, Y., & Betts, T. R. (2016) · EP Europace · doi:10.1093/europace/euw381 · Cited by 62
Plasma contact factors as therapeutic targets
Tillman, B. F., Gruber, A., McCarty, O. J. T., & Gailani, D. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.001 · Cited by 65
Antithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 69
Cost-effectiveness of Screening for Atrial Fibrillation Using Wearable Devices
Chen, W., Khurshid, S. S., Singer, D. E., Atlas, S. J., Ashburner, J. M., Ellinor, P. T., McManus, D. D., Lubitz, S. A., & Chhatwal, J. (2022) · JAMA Health Forum · doi:10.1001/jamahealthforum.2022.2419 · Cited by 61
Efficacy and safety of novel oral anticoagulants in patients with bioprosthetic valves
Yadlapati, A., Groh, C. A., Malaisrie, S. C., Gajjar, M. M., Kruse, J. T., Meyers, S. N., & PASSMAN, R. S. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0919-z · Cited by 61
Tawfik, A., BIELECKI, J. M., Krahn, M. D., Dorian, P., Hoch, J. S., Boon, H. S., Husereau, D., & Pechlivanoglou, P. (2016) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s105165 · Cited by 60
Kim, I., Kim, H.-J., Kim, T., Uhm, J., Joung, B., Lee, M., & Pak, H. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.01.015 · Cited by 63
Huiart, L., Ferdynus, C., Renoux, C., Beaugrand, A., Lafarge, S., Bruneau, L., Suissa, S., Maillard, O., & Ranouil, X. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-018180 · Cited by 61
Lee, S., Choi, E., Kwon, S., Jung, J., Han, K., Cha, M., Oh, S., & Lip, G. Y. H. (2019) · Stroke · doi:10.1161/strokeaha.119.028030 · Cited by 61
Niessner, A., Tamargo, J. L., Morais, J., Koller, L., Waßmann, S., Husted, S., Torp-Pedersen, C. T., Kjeldsen, K. P., Lewis, B. S., Drexel, H., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv676 · Cited by 60
Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life
Becattini, C., Franco, L., Beyer‐Westendorf, J., Masotti, L., Nitti, C., Vanni, S., Manina, G., Cattinelli, S., Cappelli, R., Sbrojavacca, R., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.117 · Cited by 63
Tepper, P. G., Mardekian, J., Masseria, C., Phatak, H. M., Kamble, S., Abdulsattar, Y., Petkun, W., & Lip, G. Y. H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205989 · Cited by 60
Patti, G., Pecen, L., Lucerna, M., Huber, K., Rohla, M., Renda, G., Siller-Matula, J. M., Ricci, F., Kirchhof, P. F., & Caterina, R. D. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2018.12.036 · Cited by 61
Doehner, W., Böhm, M., Boriani, G., Christersson, C., Coats, A., Haeusler, K., Jones, I., Lip, G., Metra, M., Ntaios, G., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3071 · Cited by 59
Garkina, S. V., Вавилова, Т. В., Lebedev, D. S., & Mikhaylov, E. N. (2016) · PubMed Central · doi:10.11909/j.issn.1671-5411.2016.09.010 · Cited by 60
Yagyuu, T., Kawakami, M., Ueyama, Y., Imada, M., Kurihara, M., Matsusue, Y., Imai, Y., Yamamoto, K., & Kirita, T. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-015952 · Cited by 60
Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥1, or higher?
Olesen, J. B., & Torp-Pedersen, C. T. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0154 · Cited by 59
Best, J. G., Ambler, G., Wilson, D., Lee, K., Lim, J., Shiozawa, M., Koga, M., Li, L., Lovelock, C. E., Chabriat, H., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00024-7 · Cited by 59
Pinho‐Gomes, A., Azevedo, L. F., Copland, E., Canoy, D., Nazarzadeh, M., Ramakrishnan, R., Berge, E., Sundström, J., Kotecha, D., Woodward, M., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003599 · Cited by 62
Antithrombotic therapy in patients with cerebral microbleeds
Wilson, D., & Werring, D. J. (2016) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000411 · Cited by 59
Spronk, H. M. H., Padró, T., Siland, J. E., Prochaska, J. H., Winters, J., van der Wal, A. C., Posthuma, J. J., Lowe, G. D. O., D’Alessandro, E., Wenzel, P., et al. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-07-0492 · Cited by 62
Cheng, W., Liu, W., Li, B., & Li, D. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000575 · Cited by 60
Advances in Antithrombotic Therapy
Weitz, J. I., & Chan, N. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310960 · Cited by 62
Haas, S. K., Camm, A. J., Bassand, J., Angchaisuksiri, P., Cools, F. J. S., Corbalan, R. L., Gibbs, H. H., Jacobson, B. F., Koretsune, Y., Mantovani, L. G., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.03.013 · Cited by 59
de Groot, J. R., Weiss, T. W., Kelly, P. J., Monteiro, P. F., Deharo, J., de Asmundis, C., de Sá, E. L., Waltenberger, J. L., Steffel, J., Lévy, P., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa079 · Cited by 59
Bertoméu, V., Cequier, A. R., Marín, F. R., Anguita, M. P., & Ortiz, M. R. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0169 · Cited by 58
Skaistis, J., & Tagami, T. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137444 · Cited by 62
Ibáñez, L., Sabaté, M., Vidal, X., Ballarín, E., Rottenkolber, M., Schmiedl, S., Heeke, A., Huerta, C., Martín‐Merino, E., Montero, D., et al. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14071 · Cited by 58
Oral Anticoagulation in the Elderly and Frail
Bauersachs, R. M., & Herold, J. (2020) · Hämostaseologie · doi:10.1055/s-0040-1701476 · Cited by 61
Karthikeyan, G., Connolly, S. J., Ntsekhe, M., Benz, A. P., Rangarajan, S., Lewis, G., Yun, Y., Sharma, S. K., Maklady, F., Elghamrawy, A., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.03.018 · Cited by 58
Beyond the 2020 guidelines on atrial fibrillation of the European society of cardiology
Boriani, G., Vitolo, M., Lane, D. A., Potpara, T., & Lip, G. Y. H. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.01.006 · Cited by 58
Lai, H., Huang, S., Chen, L., & Hsiao, F. (2022) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2022.104646 · Cited by 58
Shaw, J. R., Castellucci, L. A., Siegal, D. M., & Carrier, M. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.11.029 · Cited by 58
Reversal agents for current and forthcoming direct oral anticoagulants
van Es, N., Caterina, R. D., & Weitz, J. I. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad123 · Cited by 59
Wetterslev, M., Møller, M. H., Granholm, A., Hassager, C., Haase, N., Lange, T., Myatra, S. N., Hästbacka, J., Arabi, Y. M., Shen, J., et al. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000005883 · Cited by 58
Veltkamp, R. C., Korompoki, E., Harvey, K., Harvey, E. R., Fießler, C., Malzahn, U., Rücker, V., Montaner, J., Caso, V., Sibon, I., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00333-2 · Cited by 58
Simon, A., Domanovits, H., Ay, C., Sengoelge, G., Levy, J. H., & Spiel, A. O. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13706 · Cited by 58
Association Between Use of Antithrombotic Medication and Hematuria-Related Complications
Wallis, C. J. D., Juvet, T., Lee, Y., Matta, R., Herschorn, S., Kodama, R. T., Kulkarni, G. S., Satkunasivam, R., Geerts, W. H., McLeod, A. G., et al. (2017) · JAMA · doi:10.1001/jama.2017.13890 · Cited by 59
Heidbüchel, H., Dagres, N., Antz, M., Kück, K., Lazure, P., Murray, S., Carrera, C., Hindricks, G., & Vahanian, A. S. (2018) · EP Europace · doi:10.1093/europace/euy039 · Cited by 58
Tobe, S. W., Stone, J. A., Anderson, T. J., Bacon, S., CHENG, A. Y. Y., Daskalopoulou, S. S., Ezekowitz, J. A., Grégoire, J. C., Gubitz, G. J., Jain, R., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180194 · Cited by 62
Use of a Smart Watch for Early Detection of Paroxysmal Atrial Fibrillation: Validation Study
Inui, T., Kohno, H., Kawasaki, Y., Matsuura, K., Ueda, H., Tamura, Y., Watanabe, M., Inage, Y., Yakita, Y., Wakabayashi, Y., et al. (2019) · JMIR Cardio · doi:10.2196/14857 · Cited by 60
Stroke prevention strategies in high-risk patients with atrial fibrillation
Kotalczyk, A., Mazurek, M., Kalarus, Z. F., Potpara, T., & Lip, G. Y. H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00459-3 · Cited by 60
Steffel, J., Ruff, C. T., Yin, O. Q. P., Braunwald, E., Park, J., Murphy, S. A., Connolly, S. J., Antman, E. M., & Giugliano, R. P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.12.053 · Cited by 58
Tsai, C.-T., Liao, J., Chiang, C., Lin, Y., Chang, S., Lo, L., Hu, Y., Tuan, T., Chung, F., Chao, T., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.6424 · Cited by 57
Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation
Kim, D., Yang, P.-S., Sung, J.-H., Jang, E., Yu, H. T., Kim, T.-H., Uhm, J., Kim, J.-Y., Pak, H.-N., Lee, M.-H., et al. (2022) · Stroke · doi:10.1161/strokeaha.121.036757 · Cited by 57
Is diabetes a hypercoagulable state? A critical appraisal
Pomero, F., Minno, M. N. D. D., Fenoglio, L. M., Gianni, M., Ageno, W., & Dentali, F. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0746-8 · Cited by 59
Pandya, E., & Bajorek, B. V. (2016) · Patient · doi:10.1007/s40271-016-0180-1 · Cited by 59
Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis
Petryszyn, P., Niewiński, P., Staniak, A., Piotrowski, P., Well, A. R., Well, M., Jęśkowiak, I., Lip, G., & Ponikowski, P. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213198 · Cited by 50
Sulzgruber, P., Waßmann, S., Semb, A. G., Doehner, W., Widimský, P., Gremmel, T., Kaski, J. C., Savarese, G., Rosano, G. M. C., Borghi, C., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz016 · Cited by 58
Harskamp, R. E., Teichert, M., Lucassen, W. A. M., van Weert, H. C. P. M., & Lópes, R. D. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06907-8 · Cited by 57
Voško, M. R., Bocksrucker, C., Drwiła, R., Ďulíček, P., Hauer, T., Mutzenbach, J. S., Schlimp, C. J., Špinler, D., Wolf, T. A., & Zugwitz, D. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1476-2 · Cited by 56
Lee, T.-H. (2024) · Cerebrovascular Diseases Extra · doi:10.1159/000542566 · Cited by 63
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Cate, H. T., Henskens, Y., & Lance, M. D. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s126265 · Cited by 56
Huisman, M. V., Rothman, K. J., Paquette, M., Teutsch, C., Diener, H., Dubner, S., Halperin, J. L., Sheng, C., Zint, K., Elsaesser, A., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.08.018 · Cited by 56
Cardiovascular Therapies Targeting Left Atrial Appendage
Turagam, M. K., Velagapudi, P., Kar, S., Holmes, D. R., Reddy, V. Y., Refaat, M. M., Biase, L. D., Al‐Ahmed, A., Chung, M. K., Lewalter, T., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.048 · Cited by 56
Waks, J. W., PASSMAN, R. S., Matos, J. D., Reynolds, M. W., Thosani, A. J., Mela, T., Pederson, D. N., Glotzer, T. V., & ZIMETBAUM, P. J. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2018.06.027 · Cited by 58
Komen, J. J., Heerdink, E. R., Klungel, O. H., Mantel-Teeuwisse, A. K., Forslund, T., Wettermark, B., & Hjemdahl, P. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa017 · Cited by 56
Reversing factor Xa inhibitors – clinical utility of andexanet alfa
Kaatz, S. S., Bhansali, H. M., Gibbs, J., Lavender, R. C., Mahan, C. E., & Paje, D. G. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s121550 · Cited by 55
Proietti, M., Lane, D. A., Boriani, G., & Lip, G. Y. H. (2019) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.02.009 · Cited by 57
Sievert, H., Rasekh, A., Bartus, K., Morelli, R., Fang, Q., Kuropka, J., Le, D. L., Gafoor, S. A., Heuer, L., Safavi‐Naeini, P., et al. (2015) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2015.08.005 · Cited by 55
First Diagnosis of Atrial Fibrillation at the Time of Stroke
Borowsky, L. H., Regan, S., Chang, Y., Ayres, A. M., Greenberg, S. M., & Singer, D. E. (2017) · Cerebrovascular Diseases · doi:10.1159/000457809 · Cited by 54
The Impact of Risk Factors and Comorbidities on The Incidence of Atrial Fibrillation
Naser, N., Dilić, M., Durak-Nalbantić, A., Kulić, M., Pepic, E., Smajić, E., & Kušljugić, Z. (2017) · Materia Socio Medica · doi:10.5455/msm.2017.29.231-236 · Cited by 59
EHRA White Paper: knowledge gaps in arrhythmia management—status 2019
Goette, A., Auricchio, A., Boriani, G., Braunschweig, F., Brugada, J., Burri, H., Camm, A. J., Crijns, H. J. G. M., Dagres, N., Deharo, J., et al. (2019) · EP Europace · doi:10.1093/europace/euz055 · Cited by 57
Koretsune, Y., Yamashita, T., Akao, M., Atarashi, H., Ikeda, T., Okumura, K., Shimizu, W., Tsutsui, H., Toyoda, Ḱ., Hirayama, A., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0094 · Cited by 55
Pham, P., Schmidt, S., Lesko, L. J., Lip, G. Y. H., & Brown, J. D. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.3593 · Cited by 55
McGrath, E. R., Go, A. S., Chang, Y., Borowsky, L. H., Fang, M. C., Reynolds, K., & Singer, D. E. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14688 · Cited by 53
Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients
Deitelzweig, S. B., Keshishian, A. V., Li, X., Kang, A. L., Dhamane, A. D., Luo, X., Balachander, N., Rosenblatt, L. C., Mardekian, J., Pan, X., et al. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15956 · Cited by 54
Mei, D. A., Imberti, J. F., Bonini, N., Romiti, G. F., Corica, B., Proietti, M., Vitolo, M., Lip, G. Y. H., & Boriani, G. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.06.022 · Cited by 54
Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke
Yong, J. H. E., Thavorn, K., Hoch, J. S., Mamdani, M., Thorpe, K. E., Dorian, P., Sharma, M., Laupacis, A., & Gladstone, D. J. (2016) · Stroke · doi:10.1161/strokeaha.115.011979 · Cited by 54
Factor XIa Inhibitors as New Anticoagulants
Quan, M. L. C., Pinto, D. J. P., Smallheer, J. M., Ewing, W. R., Rossi, K. A., Luettgen, J. M., Seiffert, D., & Wexler, R. R. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00173 · Cited by 54
Miyazaki, M., Nakashima, A., Nakamura, Y., Sakamoto, Y., Matsuo, K., Goto, M., Uchiyama, M., Okamura, K., Mitsutake, R., Urata, H., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204814 · Cited by 58
Wang, K.-L., Lópes, R. D., Patel, M. R., Buller, H. R., Tan, D. S., Chiang, C., & Giugliano, R. P. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy802 · Cited by 54
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
Schäfer, A., Flierl, U., Berliner, D., & Bauersachs, J. K. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-06981-3 · Cited by 60
Paikin, J. S., Hirsh, J., Lauw, M. N., Eikelboom, J. W., Ginsberg, J. S., & Chan, N. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0918 · Cited by 53
Best, J. G., Arram, E., Ahmed, N., Balogun, M., Bennett, K., Bordea, E., Campos, M. G., Caverly, E., Chau, M., Cohen, H., et al. (2022) · International Journal of Stroke · doi:10.1177/17474930211057722 · Cited by 55
Zeng, S., Zheng, Y., Jiang, J., Ma, J., Zhu, W., & Cai, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.907197 · Cited by 53
Lucà, F., Oliva, F. G., Abrignani, M. G., Fusco, S. A. D., Parrini, I., Canale, M. L., Giubilato, S., Cornara, S., Nesti, M., Rao, C. M., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12185955 · Cited by 61
Landmesser, U., Skurk, C., Tzikas, A., Falk, V., Reddy, V. Y., & Windecker, S. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae398 · Cited by 56
Yiin, G. S. C., Howard, D. P. J., Paul, N. L. M., Li, L., Mehta, Z., & Rothwell, P. M. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-311947 · Cited by 53
Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation
Nielsen, P. B., Larsen, T. B., Gorst‐Rasmussen, A., Skjøth, F., Rasmussen, L. H., & Lip, G. Y. H. (2014) · CHEST Journal · doi:10.1378/chest.14-2099 · Cited by 53
Providencia, R. A., Grove, E. L., Husted, S., Barra, S., Bovéda, S., & Morais, J. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.002 · Cited by 52
Current therapies and investigational drugs for peripheral arterial disease
Suzuki, J.-I., Shimamura, M., Suda, H., Wakayama, K., Kumagai, H., Ikeda, Y., Akazawa, H., Isobe, M., Komuro, I., & Morishita, R. (2015) · Hypertension Research · doi:10.1038/hr.2015.134 · Cited by 53
Mitchell, A., Watson, M. C., Welsh, T. J., & McGrogan, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040554 · Cited by 52
Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation
Kim, D., Yang, P., Jang, E., Yu, H. T., Kim, T., Uhm, J., Kim, J., Sung, J., Pak, H., Lee, M., et al. (2020) · EP Europace · doi:10.1093/europace/euaa192 · Cited by 53
Xu, Y., & Siegal, D. M. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15466 · Cited by 54
Shiga, T., Naganuma, M., Nagao, T., Maruyama, K., Suzuki, A., Murasaki, K., & Hagiwara, N. (2015) · Journal of Arrhythmia · doi:10.1016/j.joa.2015.04.004 · Cited by 53
Weinberg, E. M., Palecki, J., & Reddy, K. R. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679934 · Cited by 52
Potpara, T., Ferro, C. J., Lip, G. Y. H., Dan, G. A., Lenarczyk, R., Mallamaci, F., Ortíz, A., Sarafidis, P. A., Ekart, R., & Dagres, N. (2019) · EP Europace · doi:10.1093/europace/euz358 · Cited by 52
Bhatia, K., Ladd, L., Carr, K., Napoli, M. D., Saver, J. L., McCullough, L. D., Farahabadi, M. H., Alsbrook, D. L., Hinduja, A., Ortiz-Garcia, J., et al. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01266-2 · Cited by 57
Effect of Oral Anticoagulants in Atrial Fibrillation Patients with Polypharmacy: A Meta-analysis
Zheng, Y., Li, S., Liu, X., Lip, G. Y. H., Guo, L., & Zhu, W. (2023) · Thrombosis and Haemostasis · doi:10.1055/s-0043-1770724 · Cited by 52
Anticoagulation in Patients with Chronic Kidney Disease
Elenjickal, E. J., Travlos, C. K., Marques, P. S., & Mavrakanas, T. A. (2023) · American Journal of Nephrology · doi:10.1159/000535546 · Cited by 56
The Diagnosis and Management of Early Deep Vein Thrombosis
Hansrani, V., Khanbhai, M., & McCollum, C. N. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_103 · Cited by 53
Burr, N. E., Lummis, K., Sood, R., Kane, J. S., & Subramanian, V. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30162-5 · Cited by 55
The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation
Murphy, A., Banerjee, A., BREITHARDT, G. E., Camm, A. J., Commerford, P., Freedman, B., González-Hermosillo, J. A., Halperin, J. L., Lau, C., Perel, P., et al. (2017) · Global Heart · doi:10.1016/j.gheart.2017.01.015 · Cited by 53
Søgaard, M., Skjøth, F., Jensen, M., Kjældgaard, J. N., Lip, G. Y. H., Larsen, T. B., & Nielsen, P. B. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011358 · Cited by 52
Milling, T. J., & Pollack, C. V. (2020) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2020.05.086 · Cited by 52
Metadata
- Authors
- Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., Yamashita, T., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Thomas Jefferson University (US)
- St George's, University of London (GB)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Carmel Medical Center (IL)
- Cardiovascular Institute Hospital (JP)
- Corresponding author
- Ruff, Christian T
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9921
- Pages
- 955-962
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2152623033
- Cited by
- 5,051
- References
- 45
- Citations by year
- 2026: 249 · 2025: 310 · 2024: 399 · 2023: 426 · 2022: 410 · 2021: 490 · 2020: 521 · 2019: 462 · 2018: 456 · 2017: 447 · 2016: 406 · 2015: 318 · 2014: 139
- FWCI
- 49.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- direct oral anticoagulants, warfarin, atrial fibrillation, stroke prevention, systemic embolism, hemorrhagic stroke, intracranial hemorrhage, gastrointestinal bleeding, major bleeding, all-cause mortality, subgroup analysis, factor Xa inhibitors, dabigatran, rivaroxaban, apixaban
- MeSH terms
- Administration, Oral, Anticoagulants, Atrial Fibrillation, Embolism, Humans, Warfarin, Randomized Controlled Trials as Topic, Treatment Outcome, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
